Competitors28 Sep 2020 14:45
GDR needs the BC platform to be a serious player but BC appear to be more interested in selling their antibody test through diagnostics division. Labs in Europe / U.S have already standardised testing on high volume platforms (Roche, Abbott, Hologic, Perkin Elmer) Only an opinion but GDR / BC are a bit late to the table and what can they compete with? price is all they will have to attract labs away from current suppliers and that is never a good strategy.
There are numerous other small players with systems placed for additional testing - Seegene, Aud Dx etc. I would love to see the SP rise above £2 but I don't feel so confident